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A phase II study of erlotinib (E) and bevacizumab (B) in patients 
(pts) with previously untreated stage IIIB/IV non-small-cell lung 
cancer (NSCLC)
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Background: In advanced NSCLC, E and B either as a single agent 
(E) or in combination with chemotherapy (B) have shown to improve 
survival. Combinations of targeted agents may prove to be effective 
and better tolerated than chemotherapy. 
Methods: This is a multicenter 2-stage phase II study (Simon’s optimal 
design; p0=40%, p1=60%, α=0.05, β=0.20) with early stopping rule 
.The primary endpoint is non-progression (NPR) at 6 weeks. When 
24/46 pts have NPR at 6 wks the treatment will be declared to have suf-
ﬁcient activity for further testing. 
Pts (PS 0-2) with advanced non-squamous NSCLC who had received 
no prior systemic anti-tumour therapy were treated with E (150mg/day) 
plus B (15mg/kg every 21 days) until disease progression or unac-
ceptable toxicity, An imaging protocol including CT, DCE-MRI and 
FDG/H20 PET was performed at weeks -1,3 and 6.
Results: Between 02/06 and 02/07, 43 pts were included; 33 evaluable 
for safety and efﬁcacy, 10 pts are too early. 
Demographics: M/F: 17/16; median age 60 (range 34-80); PS 0/1/2: 
16/13/4; smoking status: current/former/never 13/16/4. Twenty-ﬁve 
pts had stage IV disease. The most common treatment-related adverse 
events (all grades) were: rash (32%) and diarrhea (18%). Hypertension 
was observed in 2.9% of courses. Grade 3/4 adverse events (≥5%) con-
sisted of rash (31% of patients). There was 1 probable treatment-related 
death. Six pts withdrew early from the study, 2 due to toxicity (trom-
bosis and mucositis), 2 due to death (1 death for unknown reason, 1 
due to pneumonia), 2 for treatment unrelated reasons. 5 pts had E dose 
modiﬁcations for toxicity and 5 delay of B mainly for logistic reasons. 
Rate of NPR at 6 weeks 76% (25/33) with 10 (30%) PR. The median 
follow-up is 7.2 months (95% CI 4.3-8.6 months). Median TTP: 5.5 
months (95% CI 1.3 - 6.2), At this interim analysis 22/33 patients are 
alive,16/31 patients are without disease progression and 13/32 patients 
are on protocol treatment .
Conclusions: E + B was well tolerated, with a low rate of grade 3/4 ad-
verse events and no unexpected toxicities. The 75% no progression rate 
justiﬁes phase III testing in untreated advanced non-squamous NSCLC 
against platinum based chemotherapy. Updated results including cor-
relative imaging studies will be presented.
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Carbon ion radiotherapy for peripheral stage I non small-cell lung 
cancer
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Background: Some of the patients with stage I lung cancers can not 
be treated surgically because of low lung function and/or other reasons, 
development of non-surgical curative modalities are expected to 
decrease mortality from lung cancer. Carbon ion radiotherapy (CIRT) 
is a promising modality because of its excellent dose localization and 
high biological effects on a tumor. From 1994 to 1999, we conducted a 
phase I / II clinical trial for stage I non-small cell lung cancer (NSCLC) 
by using carbon ion beams alone. And demonstrated an optimal dose 
of 90GyE in 18 fractions over 6 weeks and 72GyE in 9 fractions over 3 
weeks, achieving more than 95% local control with minimum pulmo-
nary damage. In the present study, we conducted a phase II clinical trial 
for stage NSCLC to determine the local control and the survival rates.
Methods: One hundred twenty-nine patients with 131 primary lesions 
were treated from 1999 to 2003 in National Institute of Radiologi-
cal Sciences, Research Center Hospital for Charged Particle Therapy, 
Japan. The patients consisted of 37 females and 92 males, with a mean 
age of the patients 74.5 years. The T1 and T2 numbers were 72 and 59, 
respectively, and the average tumor size in diameter was 31.5 mm. By 
histology, the tumors broke down into 85 adenocarcinomas, 43 squa-
mous cell carcinomas, two large cell carcinomas and one adenosqua-
mous cell carcinoma. A primary tumor was treated with carbon beam 
alone using the ﬁxed total dose of 72GyE in 9 fractions over 3 weeks, 
or 52.8GyE for stage IA, 60GyE for stage IB over one week. Most of 
targets were irradiated from obliquely from four directions. A respira-
tory-gated irradiation system was used for irradiation in each case. 
Local control and survival were determined by using the Kaplan-Meyer 
method and the data were statistically processed by using the long-rank 
test (the signiﬁcance level was 0.05).
Results: The cumulative local control rate for all lesions was 94.7% at 
58 months after CIRT. There was no statistical difference in the local 
control rate between T1 and T2 (p=0.061), and between the histolo-
gies (squamous cell carcinoma vs. non-squamous cell carcinoma) 
(p=0.077). Overall 5-year survival rates after CIRT were 68.7% in stage 
IA (n=69), 46.4% in stage IB (n=56). No toxic reactions were observed 
in the skin and no adverse effects worse than grade III were detected.
Conclusions: Carbon beam radiotherapy, a new therapy modality with 
superior beneﬁts in terms of QOL and ADL, has been proven to be a 
valid alternative to surgery for stage I NSCLC and to offer particular 
beneﬁts especially for the poor surgical candidates.
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FDG-PET allows identification of radioresistant areas within the 
tumor during and after radiation treatment of NSCLC
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Background: In recent years, it has become clear that tumors are not 
homogeneous, also for radioresistance. The identiﬁcation of areas of 
radioresistance within the same tumor is therefore of great interest, for 
it may allow selective boosting of these zones. This study therefore 
addressed two critical questions needed for escalating dose to speciﬁc 
areas within the tumor: 1. Where does the residual disease occur after 
treatment based on FDG PET imaging? 2. Does the high FDG uptake 
zone remain stable within the tumor during a course of radiotherapy? 
Methods: 1. Location of residual disease within the tumor. Six patients 
with inoperable NSCLC, stage I-III, treated with radical radiotherapy, 
